214 related articles for article (PubMed ID: 30582658)
1. An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing.
Baumhoer D; Amary F; Flanagan AM
Genes Chromosomes Cancer; 2019 Feb; 58(2):88-99. PubMed ID: 30582658
[TBL] [Abstract][Full Text] [Related]
2. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.
Cleven AH; Höcker S; Briaire-de Bruijn I; Szuhai K; Cleton-Jansen AM; Bovée JV
Am J Surg Pathol; 2015 Nov; 39(11):1576-83. PubMed ID: 26457357
[TBL] [Abstract][Full Text] [Related]
3. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
Gong L; Bui MM; Zhang W; Sun X; Zhang M; Yi D
Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329
[TBL] [Abstract][Full Text] [Related]
4. Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma.
Lam SW; Cleven AHG; Kroon HM; Briaire-de Bruijn IH; Szuhai K; Bovée JVMG
Virchows Arch; 2020 Mar; 476(3):455-463. PubMed ID: 31768625
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy.
Schaefer IM; Fletcher JA; Nielsen GP; Shih AR; Ferrone ML; Hornick JL; Qian X
Cancer Cytopathol; 2018 Aug; 126(8):552-566. PubMed ID: 29757500
[TBL] [Abstract][Full Text] [Related]
6. The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma.
Amary MF; Berisha F; Mozela R; Gibbons R; Guttridge A; O'Donnell P; Baumhoer D; Tirabosco R; Flanagan AM
Histopathology; 2016 Jul; 69(1):121-7. PubMed ID: 26844533
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of histone 3 mutations in osteoclast-rich bone tumors.
Nohr E; Lee LH; Cates JM; Perizzolo M; Itani D
Hum Pathol; 2017 Oct; 68():119-127. PubMed ID: 28882701
[TBL] [Abstract][Full Text] [Related]
8. Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone.
Ali NM; Niada S; Brini AT; Morris MR; Kurusamy S; Alholle A; Huen D; Antonescu CR; Tirode F; Sumathi V; Latif F
J Pathol; 2019 Feb; 247(2):166-176. PubMed ID: 30281149
[TBL] [Abstract][Full Text] [Related]
9. [Molecular pathology in the diagnosis of bone tumors: current concepts].
Baumhoer D; Höller S
Pathologe; 2020 Mar; 41(2):106-115. PubMed ID: 31993697
[TBL] [Abstract][Full Text] [Related]
10. Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma.
Venneker S; Szuhai K; Hogendoorn PCW; Bovée JVMG
Virchows Arch; 2020 Jan; 476(1):135-146. PubMed ID: 31728625
[TBL] [Abstract][Full Text] [Related]
11. Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.
Lucas CG; Grenert JP; Horvai A
Arch Pathol Lab Med; 2021 Aug; 145(8):1009-1017. PubMed ID: 33147331
[TBL] [Abstract][Full Text] [Related]
12. What's new in bone forming tumours of the skeleton?
Franceschini N; Lam SW; Cleton-Jansen AM; Bovée JVMG
Virchows Arch; 2020 Jan; 476(1):147-157. PubMed ID: 31741049
[TBL] [Abstract][Full Text] [Related]
13. Genetic profiling of a chondroblastoma-like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1-FGFR1 gene fusion.
Saba KH; Cornmark L; Rissler M; Fioretos T; Åström K; Haglund F; Rosenberg AE; Brosjö O; Nord KH
Genes Chromosomes Cancer; 2019 Oct; 58(10):731-736. PubMed ID: 31066955
[TBL] [Abstract][Full Text] [Related]
14. Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone.
Righi A; Mancini I; Gambarotti M; Picci P; Gamberi G; Marraccini C; Dei Tos AP; Simi L; Pinzani P; Franchi A
Hum Pathol; 2017 Oct; 68():128-135. PubMed ID: 28899740
[TBL] [Abstract][Full Text] [Related]
15. Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group.
Tallini G; Dorfman H; Brys P; Dal Cin P; De Wever I; Fletcher CD; Jonson K; Mandahl N; Mertens F; Mitelman F; Rosai J; Rydholm A; Samson I; Sciot R; Van den Berghe H; Vanni R; Willén H
J Pathol; 2002 Feb; 196(2):194-203. PubMed ID: 11793371
[TBL] [Abstract][Full Text] [Related]
16. Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis.
Lam SW; van Langevelde K; Suurmeijer AJH; Cleven AHG; Bovée JVMG
Histopathology; 2019 Dec; 75(6):843-852. PubMed ID: 31297850
[TBL] [Abstract][Full Text] [Related]
17. GRM1 Immunohistochemistry Distinguishes Chondromyxoid Fibroma From its Histologic Mimics.
Toland AMS; Lam SW; Varma S; Wang A; Howitt BE; Kunder CA; Kerr DA; Szuhai K; Bovée JVMG; Charville GW
Am J Surg Pathol; 2022 Oct; 46(10):1407-1414. PubMed ID: 35650682
[TBL] [Abstract][Full Text] [Related]
18. Integrating Morphology and Genetics in the Diagnosis of Cartilage Tumors.
de Andrea CE; San-Julian M; Bovée JVMG
Surg Pathol Clin; 2017 Sep; 10(3):537-552. PubMed ID: 28797501
[TBL] [Abstract][Full Text] [Related]
19. Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone.
Yoshida KI; Nakano Y; Honda-Kitahara M; Wakai S; Motoi T; Ogura K; Sano N; Shibata T; Okuma T; Iwata S; Kawai A; Ichimura K; Yoshida A
Mod Pathol; 2019 Dec; 32(12):1751-1761. PubMed ID: 31285528
[TBL] [Abstract][Full Text] [Related]
20. Recurrent rearrangements of FOS and FOSB define osteoblastoma.
Fittall MW; Mifsud W; Pillay N; Ye H; Strobl AC; Verfaillie A; Demeulemeester J; Zhang L; Berisha F; Tarabichi M; Young MD; Miranda E; Tarpey PS; Tirabosco R; Amary F; Grigoriadis AE; Stratton MR; Van Loo P; Antonescu CR; Campbell PJ; Flanagan AM; Behjati S
Nat Commun; 2018 Jun; 9(1):2150. PubMed ID: 29858576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
